[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635491":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":47,"collaborators":49,"id":53,"slug":18,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":18,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":18,"enrollmentInfo":60,"targetDuration":18,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":18,"overallStatus":73,"whyStopped":18,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Yale University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"AcamproSync","EXPERIMENTAL","Participants will 1.) use the AcamproSync system which directly measures acamprosate adherence, 2) receive a personalized, adherence intervention grounded in the empiric LifeSteps Cognitive Behavioral Therapy framework and 3) self-management and introspection into alcohol use patterns through ecological momentary assessments (EMA) of drinking and alcohol craving.",[13],"Device: AcamproSync",{"label":15,"type":16,"description":17,"interventionNames":18},"Control (Treatment as Usual)","NO_INTERVENTION","Participants will receive treatment as usual.",null,[20],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":18},"DEVICE","AcamproSync, is an innovative behavioral intervention to support acamprosate adherence in individuals with ALD. It comprises three components: 1) a digital pill system that directly measures acamprosate adherence, 2) a personalized, adherence intervention grounded in the empiric LifeSteps Cognitive Behavioral Therapy framework and 3) self-management and introspection into alcohol use patterns through ecological momentary assessments (EMA) of drinking and alcohol craving.",[9],[25],{"name":26,"affiliation":5,"role":27},"Charlotte Goldfine","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":18,"email":33},"Charlotte Goldfine, MD","CONTACT","203-785-2353","charlotte.goldfine@yale.edu",[35],{"facility":36,"status":18,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":18},"Yale","New Haven","Connecticut","06520","United States",{"type":42,"coordinates":43},"Point",[44,45],-72.92816,41.30815,{"lat":45,"lon":44},{"type":48,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[50],{"name":51,"class":52},"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","NIH","100635491",false,"NCT07553377","A Digital Pill System to Measure and Support Acamprosate Adherence in Individuals With Alcohol Associated Liver Disease","Inclusion Criteria:\n\n* Being treated for AUD\n* Diagnosed with DSM-5 moderate to severe AUD\n* Screens positive ALD utilizing non-invasive blood tests\n* Planned initiation of acamprosate\n\nExclusion Criteria:\n\n* History of hypersensitivity to acamprosate\n* Allergy to magnesium or silver\n* Severe renal impairment (creatinine clearance of 30mL\u002Fmin or less)","ALL","18 Years",{"count":61,"type":62},50,"ESTIMATED","INTERVENTIONAL",[65],"NA","This study seeks to develop and test a novel digital pill system (DPS) that measures real-time medication ingestion and pairs it with a cognitive behavioral therapy (CBT)-based intervention to provide personalized, data-driven adherence support, with the long-term goal of providing new and improved personalized support and increase medication adherence for people with AUD and ALD.",[68,69,70,71,72],"Alcohol Use Disorder","Alcohol Associated Liver Disease","Medications for Alcohol Use Disorder","Behavioral Medicine","Medication Adherence","NOT_YET_RECRUITING","2026-04-21",{"date":76,"type":77},"2026-04-28","ACTUAL",{"date":79,"type":62},"2027-10",{"date":81,"type":62},"2030-10",{"name":5,"class":6},1]